Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS talactoferrin in severe sepsis
NL-OMON35780Phase 2Active, not recruiting
- Sponsor
- Agennix AG
- Start
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sepsis and septic shock comparing Talactoferrin alfa + standard care with Placebo + standard care (2 arms). Primary endpoint: 28-day all-cause mortality. Started Nov 2011; status: active, not recruiting.
02
Drugs
lactoferrin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NL-OMON35780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35780.